Meeting
2021 ASCO Annual Meeting
Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who receive second-line immunotherapy.
Authors
Benjamin Miron
Fox Chase Cancer Center, Philadelphia, PA
Benjamin Miron , Elizabeth A. Handorf , Kevin Zarrabi , Matthew R. Zibelman , Pooja Ghatalia , Fern Anari , Elizabeth R. Plimack , Daniel M. Geynisman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4535)
DOI
10.1200/JCO.2021.39.15_suppl.4535
Abstract #
4535
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Treatment trends for metastatic urothelial carcinoma across eight Mexican centers: A global oncology perspective.
First Author: Evelyn Lilian Beas-Lozano
Poster
2024 ASCO Genitourinary Cancers Symposium
Pemetrexed (PEM) maintenance versus observation (OBS) in patients (pts) with advanced urothelial carcinoma (aUC) who completed first-line (1L) platinum-based chemotherapy (CTx) without disease progression (PREMIER, KCSG GU16-05).
First Author: Inkeun Park
Poster
2023 ASCO Annual Meeting
Outcomes by complete response to first-line pembrolizumab or platinum-based chemotherapy in advanced urothelial carcinoma (UC) in KEYNOTE-361.
First Author: Ozgur Ozyilkan
Poster
2023 ASCO Genitourinary Cancers Symposium
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.
First Author: Srikala S. Sridhar